Effectiveness of palonosetron versus granisetron in preventing chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis

Hsu, Yu‐Chen; Chen, Ching‐Yao; Tam, Ka‐Wai; Hsu, Chin-Yu

doi:10.1007/s00228-021-03157-2

Cited by 14 publications

(9 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Palonosetron, a second-generation 5-HT 3 RA, is considered more effective in preventing delayed CINV due to its extended half-life and increased receptor affinity. 29 Since 2016, palonosetron has surpassed tropisetron as the most frequently prescribed 5-HT 3 RA, reflecting its superior efficacy in CINV control. However, there was an excessive use of 5-HT 3 RAs, consistent with previous reports from China 19 and Brazil.…”

Section: Discussionmentioning

confidence: 99%

Retrospective analysis of real‐world prescribing data for managing cisplatin‐based chemotherapy‐induced nausea and vomiting in China

Si,

Zhang,

Ding

et al. 2024

Cancer Medicine

View full text Add to dashboard Cite

BackgroundThe current utilization of neurokinin‐1 receptor antagonists (NK1RAs) and the impact of updated guidelines on prescription patterns of antiemetic drugs among Chinese patients receiving highly emetogenic chemotherapy (HEC) remain undetermined. This study aims to analyze the present situation of Chinese cancer patients using antiemetic drugs and assess the appropriateness of antiemetic regimens.MethodsPrescription data were collected between January 2015 and December 2020 from cancer patients receiving cisplatin‐based chemotherapy at 76 hospitals in six major cities in China. Trends in the use of antiemetic drugs, prescribing patterns and adherence to antiemetic guidelines were assessed.ResultsAmong the 108,611 patients included in this study, 6 classes and 17 antiemetic drugs were identified as monotherapy or combination therapy in 93,872 patients (86.4%), whereas 14,739 patients (13.6%) were administered no antiemetic treatment. 5‐hydroxytryptamine 3 receptor antagonists (5‐HT3RAs) and glucocorticoids were the two most frequently used classes of antiemetics, followed by metoclopramide. NK1RAs were underused across the six cities, only 9332 (8.6%) and 1655 (1.5%) cisplatin‐based treatments were prescribed aprepitant and fosaprepitant, respectively. Prescriptions of olanzapine and lorazepam were very low throughout the study period. In prescribing patterns of antiemetic drugs, dual combination regimens were the most common (40.0%), followed by triple combination therapy and monotherapy (25.8% and 15.1%, respectively). Overall, the adherence to antiemetic guidelines for patients undergoing cisplatin‐based regimens was only 8.1% due to inadequate prescription of antiemetic drugs. Finally, our study also revealed that 5‐HT3RAs and glucocorticoids were overprescribed in 8.8% and 1.6% of patients, respectively.ConclusionsThe current study reveals suboptimal utilization of recommended antiemetic drugs for managing cisplatin‐based HEC‐induced nausea and vomiting in China. Improving the management of CINV is crucial, and these findings provide valuable insights into optimizing antiemetic drug practices.

show abstract

Section: Discussionmentioning

confidence: 99%

Retrospective analysis of real‐world prescribing data for managing cisplatin‐based chemotherapy‐induced nausea and vomiting in China

Si,

Zhang,

Ding

et al. 2024

Cancer Medicine

View full text Add to dashboard Cite

show abstract

“…One mechanism of CINV involves the binding of substance P to the NK 1 receptor, and a significant increase in plasma substance P levels has been reported, especially in the delayed phase of CINV 29 . Palonosetron, a 5‐HT 3 RA, specifically inhibits “crosstalk” between the NK 1 and 5‐HT 3 receptor signaling pathways 30–32 and is reportedly more effective against delayed‐phase CINV than conventional 5‐HT 3 RAs 33–35 . Furthermore, a subgroup analysis of the PROTECT study 33 reported that palonosetron is particularly effective in patients <55 years old and women.…”

Section: Discussionmentioning

confidence: 99%

Influence of menopause on chemotherapy‐induced nausea and vomiting in highly emetogenic chemotherapy for breast cancer: A retrospective observational study

Yokokawa,

Suzuki,

Tsuji

et al. 2023

Cancer Medicine

View full text Add to dashboard Cite

BackgroundFemale sex and younger age are reported risk factors for chemotherapy‐induced nausea and vomiting (CINV) in highly emetogenic chemotherapy, but the underlying mechanism has not been elucidated. The purpose of this study was to clarify the impact of menopause on CINV.MethodsThis retrospective observational study analyzed data from consecutive patients who received their first cycle of perioperative anthracycline‐based chemotherapy for breast cancer between January 2018 and June 2020. The endpoints were association between CINV (vomiting, ≥Grade 2 nausea, complete response [CR] failure) and menopause as well as the association between CINV and follicle‐stimulating hormone [FSH]/estradiol [E2].ResultsData for 639 patients were analyzed. Among these patients, 109 (17.1%) received olanzapine (four antiemetic combinations) and 530 (82.9%) did not (three antiemetic combinations). Premenopausal state (amenorrhea lasting ≥12 months) was significantly associated with ≥Grade 2 nausea and CR failure in univariate analysis but not in multivariate analysis. The premenopausal FSH/E2 group (defined by serum levels; FSH <40 mIU/mL and E2 ≥20 pg/mL) had a significantly higher rate of ≥Grade 2 nausea than the postmenopausal FSH/E2 group (FSH ≥40 mIU/mL and E2 <20 pg/mL) (48.8% vs. 18.8%, p = 0.023).ConclusionsOur results suggest that changes in FSH and E2 due to menopause may affect the severity of nausea and that FSH and E2 (especially FSH) levels might be useful indicators for CINV risk assessment.

show abstract

“…In a very recently published meta-analysis [14] , the e cacy of palonosetron and granisetron in both dual and triplet anti-emetic combinations was compared in patients receiving MEC and HEC. According to this meta-analysis which including the ve studies comparing triplet antiemetic therapy mentioned above, palonosetron and granisetron were equally effective in preventing acute CINV, whereas response rates of palonosetron in the delayed phase were slightly higher than granisetron.…”

Section: Suzuki Et Al's Triple Studymentioning

confidence: 99%

Comparison of granisetron and palonosetron in triplet anti-emetic prophylaxis in non-small cell lung cancer patients receiving cisplatin-based highly emetogenic chemotherapy

Araz

Beypınar

İnci

et al. 2022

Preprint

View full text Add to dashboard Cite

Purpose: We compared the efficacy of first-generation granisetron and second-generation palonosetron in triplet anti-emetic prophylaxis in patients with non-small cell lung cancer (NSLC) receiving cisplatin-based high emetogenic chemotherapy (HEC).Methods: This prospective, multicenter, non-randomized, observational study was conducted between June 2018 and December 2021. Patients diagnosed with NSCLC who received triplet anti-emetic prophylactic treatment with aprepitant and dexamethasone plus granisetron or palonosetron before the first cycle of chemotherapy were included in the study.At the end of the first week after chemotherapy, the emesis scale was applied to the patients during the outpatientcontrol. The primary endpoint was complete response (CR) and total control (TC).Results: One hundred twenty-one patients were included in the study. Sixty-one patients were in the granisetron group and 60 patients were in the palonosetron group. CR was higher with granisetron in the acute phase (70.5% vs. 58.3%, p=0.16; respectively) and higher with palonosetron in the delayed phase (61.7% vs. 55.7%, p=0.5; respectively), although not statistically significant. The TC rates were also not significantly different between the groups (54.1% vs.57.6%, p=0.69). Conclusion: There was no significant difference between granisetron and palonosetron in both acute and delayed control of emesis in NSCLC patients receiving cisplatin-based HEC.

show abstract

Effectiveness of palonosetron versus granisetron in preventing chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis

Cited by 14 publications

References 42 publications

Retrospective analysis of real‐world prescribing data for managing cisplatin‐based chemotherapy‐induced nausea and vomiting in China

Retrospective analysis of real‐world prescribing data for managing cisplatin‐based chemotherapy‐induced nausea and vomiting in China

Influence of menopause on chemotherapy‐induced nausea and vomiting in highly emetogenic chemotherapy for breast cancer: A retrospective observational study

Comparison of granisetron and palonosetron in triplet anti-emetic prophylaxis in non-small cell lung cancer patients receiving cisplatin-based highly emetogenic chemotherapy

Contact Info

Product

Resources

About